Elanco Animal Health Inc (ELAN): R&D Expense
$368.00M
Year ended 2025-12-31
$371.00M
Trailing 12 months to 2026-06-30
+4.7%
3-year compound annual growth
+2.3%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $368.00M | +7.0% | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | $344.00M | +5.2% | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | $327.00M | +1.9% | 2026-02-24, From 2023-01-01 |
| 2022-12-31 | $321.00M | -13.0% | 2025-02-25, From 2022-01-01 |
| 2021-12-31 | $369.00M | +12.2% | 2024-02-26, From 2021-01-01 |
| 2020-12-31 | $329.00M | +21.9% | 2023-03-01, From 2020-01-01 |
| 2019-12-31 | $270.00M | +9.5% | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | $246.60M | -2.0% | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | $251.70M | -5.3% | 2020-02-28, From 2017-01-01 |
| 2016-12-31 | $265.80M | n/a | 2019-02-20, From 2016-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Elanco Animal Health Inc (ELAN) | 2025-12-31 | $368.00M | +7.0% |
| Jazz Pharmaceuticals plc (JAZZ) | 2025-12-31 | $782.74M | -11.5% |
| Perrigo Co PLC (PRGO) | 2025-12-31 | $95.40M | -15.0% |
| BeOne Medicines Ltd. (ONC) | 2025-12-31 | $2.15B | +9.9% |
| Alnylam Pharmaceuticals, Inc. (ALNY) | 2025-12-31 | $1.32B | +17.2% |
| Organon & Co. (OGN) | 2025-12-31 | $366.00M | -22.0% |
| BioMarin Pharmaceutical Inc (BMRN) | 2025-12-31 | $921.93M | +23.4% |
| United Therapeutics Corp (UTHR) | 2025-12-31 | $550.00M | +14.3% |
| Amneal Pharmaceuticals, Inc. (AMRX) | 2025-12-31 | $186.18M | -2.4% |
Compare ELAN, JAZZ, PRGO, ONC side by side · Screen every company in Pharmaceutical Preparations ↗